The global multiomics market size was estimated at around USD 2.08 billion in 2022 and it is projected to hit around USD 8.67 billion by 2032, growing at a CAGR of 15.34% from 2023 to 2032. The multiomics market in the United States was accounted for USD 887 million in 2022.
Key Pointers
- North America led the market with largest share of 49% in 2022
- Asia Pacific is anticipated to grow at a significant CAGR of 17.86% over forecast period.
- By Product & Service, the product segment accounted for the maximum market share of 61% in 2022.
- By Product & Service, the service segment is expected to grow at the fastest CAGR of 17.43% from 2023 to 2032.
- By Type, the single-cell multiomics segment is expected to expand at the highest CAGR of 17.85% during forecast period.
- By Platform, the genomics segment dominated the market with a revenue share of 41% in 2022.
- By Platform, the metabolomics segment is expected to grow at the notable CAGR of 17.55% from 2023 to 2032.
- By Application, the cell biology segment generated the maximum market share of 39% in 2022.
- By Application, the oncology segment is predicted to grow at the fastest CAGR of 18.04% over forecast period.
- By End-use, the academic and research institutes segment registered the maximum market share of 51% in 2022.
- By End-use, the pharmaceutical and biotechnology companies segment is projected to register the fastest CAGR of 17.54% during forecast period.
The multiomics market, a dynamic and burgeoning sector within life sciences, is revolutionizing our approach to understanding biological systems. This overview provides a comprehensive insight into the multiomics market, highlighting its fundamental principles, key components, applications, and the driving forces behind its rapid growth.
Market Growth
The growth of the multiomics market is propelled by a confluence of factors driving innovation and adoption across diverse industries. Technological advancements, particularly in high-throughput sequencing and mass spectrometry, have significantly enhanced the efficiency and affordability of omics data generation. The increasing recognition of multiomics applications in personalized medicine, drug discovery, agriculture, and environmental science further fuels market expansion. The demand for a comprehensive understanding of biological systems, coupled with the rising emphasis on precision medicine, contributes to the market’s upward trajectory. Additionally, collaborative efforts between academia, industry, and technology providers are fostering the development of standardized protocols and analytical tools, addressing challenges and unlocking new opportunities in the multiomics landscape.
Get a Sample: https://www.visionresearchreports.com/report/sample/40933
Report Scope of the Multiomics Market
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 15.34% |
| Market Revenue by 2032 | USD 8.67 billion |
| Revenue Share of North America in 2022 | 49% |
| CAGR of Asia Pacific from 2023 to 2032 | 17.86% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units)Companies Covered |
| Companies Covered | BD; Thermo Fisher Scientific Inc.; Illumina, Inc; Danaher; PerkinElmer Inc.; Shimadzu Corporation; Bruker; QIAGEN; Agilent Technologies, Inc.; BGI |
Read More: https://www.heathcareinsights.com/non-magnetic-wheelchair-market/
Market Dynamics
Drivers
Diverse Applications:
The versatility of multiomics applications across industries, including healthcare, pharmaceuticals, agriculture, and environmental science, contributes to its widespread adoption and market growth.
Precision Medicine:
The emphasis on personalized medicine, leveraging the unique molecular profiles identified through multiomics, fuels the demand for tailored and more effective treatment strategies, acting as a significant driver for market expansion.
Restraints
Data Complexity and Interpretation Challenges:
The integration and interpretation of vast and diverse omics data sets pose significant challenges, including the need for robust computational infrastructure and standardized analytical methods, acting as a restraint on the seamless implementation of multiomics approaches.
Standardization Issues:
Lack of standardized protocols and data formats across different omics disciplines hinders interoperability and data comparability, presenting a barrier to the widespread adoption and integration of multiomics in research and industry.
Opportunities
Advancements in Single-Cell Omics:
Ongoing developments in single-cell omics technologies present an exciting opportunity for the multiomics market, offering a more granular understanding of cellular heterogeneity and further expanding the scope of applications in precision medicine and developmental biology.
Artificial Intelligence and Machine Learning Integration:
The integration of artificial intelligence (AI) and machine learning (ML) into multiomics data analysis holds immense potential for enhancing the efficiency and accuracy of data interpretation, uncovering hidden patterns, and driving new insights into complex biological interactions.
Product & Service Insights
The product segment accounted for the largest market share of 61% in 2022. The products are further segmented into instruments, consumables, and software. The growing developments and increasing product launches are expected to drive the segment growth. Companies are undergoing partnerships to develop novel platforms and instruments for multiomic research and analysis.
- For instance, in April 2023, Bio-Techne collaborated with Lunaphore to develop a fully automated spatial multiomics solution.
The service segment is projected to grow at the fastest CAGR of 17.43% from 2023 to 2032. Due to the increasing demand, participants are offering numerous services focusing on multiomics. This service integrates various omics platforms, including transcriptomics, genomics, and proteomics. Thus, increasing service offerings are anticipated to drive the segment growth in the coming years.
- For instance, in September 2023, Psomagen, a multiomics contract research organization, introduced Spatial Biology services.
Type Insights
Based on type, the multiomics market is segmented into single-cell multiomics and bulk multiomics. The bulk multiomics segment dominated the type segment in 2022. Typically, bulk multiomics is essential for systematically explaining disorder pathogenesis and different phenotypes at the individual level. The various advantages of bulk multiomics can be attributed to the segment’s dominance. These advantages include the simple experimental process and affordable large-scale sample dissection.
The single-cell multiomics segment is anticipated to grow at the fastest CAGR of 17.85% during 2023-2032. The higher growth rate is attributed to the increasing demand for single-cell multiomics to understand complex biological systems. In addition, the participants are focusing on these types of products. This solution combines two assays in a single platform and offers deeper insight into therapy relapse and resistance. Such initiatives and product launches are anticipated to boost the segment growth over the forecast period.
- For instance, in October 2020, Mission Bio, Inc. introduced a complete Tapestri Single-cell Multiomics Solution to develop precision cancer therapies.
Platform Insights
The genomics segment led the market with a revenue share of 41% in 2022. There has been development of several advanced products in the genomics industry. Moreover, companies are increasing their offerings in this segment, which further propels the segment’s growth. This offering can help in the interpretation of genomic data and in designing precision treatments. Thus, launches focusing on genomic data interpretation are expected to drive segment growth over the forecast period.
- For instance, in May 2023, Google Cloud introduced an AI-powered Multiomics Suite.
The metabolomics segment is anticipated to grow at the noteworthy CAGR of 17.55% from 2023 to 2032. The increasing prevalence of cancer across the world and the rising number of studies focusing on multiomics approaches for cancer research are expected to drive the segment growth.
Application Insights
The cell biology segment held the largest revenue share of 39% in 2022. Integrating multiomics approaches is revolutionizing the understanding of cellular biology within the contexts of both health and disease. Moreover, numerous solutions are available to understand cell biology. For instance, in February 2023, BioSkryb Genomics introduced two platforms that can enable single-cell multiomic analysis. Such products can help in the understanding of cell biology using multiomic platforms.
The oncology segment is expected to grow at the fastest CAGR of 18.04% from 2023 to 2032. The rising incidences of cancer and the growing utility of multiomics for cancer are anticipated to drive the segment growth. Researchers and companies are undertaking numerous efforts to help cancer patients using multi-omic approaches.
End-use Insights
The academic and research institutes segment captured the largest market share of 51% in 2022. The increasing studies and research focusing on multiomics approaches, including genomics, proteomics, metabolomics, and transcriptomics, are anticipated to drive segment growth over the forecast period. Moreover, this segment is receiving funding and investment for conducting research in this field.
- For instance, in September 2023, the National Institutes of Health established the Multiomics for Health and Disease Consortium and provided USD 50.3 million for multiomics research.
The pharmaceutical and biotechnology companies segment is projected to register the fastest CAGR of 17.54% from 2023 to 2032, owing to the potential benefits that multiomics technologies offer in drug discovery, development, and personalized medicine. Thus, the adoption of multiomics by biotechnology and pharmaceutical companies is anticipated to increase significantly to accelerate drug discovery and development.
Regional Insights
North America dominated the market with a share of 49% in 2022, and the region is projected to register the fastest growth throughout the forecast period. The presence of key players in the region supports the highest revenue share. Moreover, companies are undertaking numerous efforts to strengthen their presence is also fueling regional industry.
- For instance, in February 2023, Tempus, the U.S.-based company, collaborated with Actuate Therapeutics to help discover and further validate biomarker profiles in patients who have cancer.
Asia Pacific is expected to grow at a significant CAGR of 17.86% from 2023 to 2032. The growth of the region can be attributed to various factors, including the rising prevalence of chronic conditions, the widespread product adoption for analysis and visualization, and technological advances coupled with rising research and development (R&D) investments. Moreover, various companies are introducing studies based on multiomics.
- For instance, in May 2021, using a multiomics approach, Burning Rock Biotech Limited introduced the PRESCIENT study, the first blood-based, pan-cancer early-detection study in China.
Multiomics Market Report Segmentations:
By Product & Service
- Products
- Instruments
- Consumables
- Software
- Services
By Type
- Single-cell Multiomics
- Bulk Multiomics
By Platform
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
By Application
- Cell Biology
- Oncology
- Neurology
- Immunology
By End-use
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/40933
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308